Loading...
Loading...
NEW YORK, NY · CIK 0001263508
New positions
12
Added to
21
Trimmed
7
Exited
11
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $22.77B across 122 positions in their Q3 2021 SEC 13F filing (period ending 2021-09-30). The top 10 positions account for 82.7% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | SGENUSDSeagen Inc. | $8.03B | 35.26% | - |
| 2 | ONCBeiGene, Ltd. | $4.24B | 18.60% | - |
| 3 | INCYIncyte Corporation | $2.20B | 9.67% | +0.0% |
| 4 | KODKodiak Sciences Inc. | $1.41B | 6.19% | +3.8% |
| 5 | ASNDUSDAscendis Pharma A/S | $723.89M | 3.18% | +28.3% |
| 6 | ACADACADIA Pharmaceuticals Inc. | $696.14M | 3.06% | - |
| 7 | BMRNBioMarin Pharmaceutical Inc. | $588.99M | 2.59% | +0.4% |
| 8 | ARGXargenx SE | $338.11M | 1.48% | - |
| 9 | PRLDPrelude Therapeutics Inc. | $316.37M | 1.39% | - |
| 10 | NVTA1EURInvitae Corporation | $280.70M | 1.23% | -3.7% |
| Stock | Value | Shares |
|---|---|---|
| DICE Therapeutics, Inc. | $19.27M | 588,235 |
| SRZNSurrozen, Inc. | $17.70M | 2,500,000 |
| TCRXTscan Therapeutics, Inc. | $11.88M | 1,425,000 |
| TNGXTango Therapeutics, Inc. | $9.70M | 750,000 |
| Amryt Pharma plc | $6.24M | 518,380 |
| KURAKura Oncology, Inc. | $5.70M | 304,158 |
| ATYRaTyr Pharma, Inc. | $5.67M | 625,000 |
| CCXIEURChemoCentryx, Inc. | $5.15M | 301,195 |
| VINCVincerx Pharma, Inc. | $3.90M | 241,379 |
| SERASera Prognostics, Inc. | $2.24M | 201,562 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.